Dec 06, 2021 7:30am EST Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs
Nov 16, 2021 7:30am EST Mydecine Reports Third Quarter 2021 Financial Results and Provides Business Update
Nov 10, 2021 7:30am EST Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’ Veterans & Families Forum on November 10, 2021
Nov 03, 2021 7:30am EDT Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion Technology to Traditional Medicine Ingredients
Oct 27, 2021 7:30am EDT Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin
Oct 05, 2021 7:30am EDT Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson
Sep 22, 2021 7:30am EDT Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data
Sep 07, 2021 7:30am EDT Mydecine Innovations Group Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial